{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:25:41Z","timestamp":1783441541107,"version":"3.54.6"},"reference-count":9,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jdcr.2020.05.002","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T12:39:51Z","timestamp":1589632791000},"page":"637-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo"],"prefix":"10.1016","volume":"6","author":[{"given":"Shanthi","family":"Narla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Oska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis B.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat H.","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jdcr.2020.05.002_bib1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s13555-019-00329-y","article-title":"Scoping review on the use of drugs targeting JAK\/STAT Pathway in atopic dermatitis, vitiligo, and alopecia areata","volume":"9","author":"Montilla","year":"2019","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jdcr.2020.05.002_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jdcr.2020.05.002_bib3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jdcr.2020.05.002_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jaad.2018.04.018","article-title":"Topical Janus kinase inhibitors: a review of applications in dermatology","volume":"79","author":"Hosking","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2020.05.002_bib5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"issue":"9993","key":"10.1016\/j.jdcr.2020.05.002_bib6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jdcr.2020.05.002_bib7","series-title":"Creatine phosphokinase","author":"Aujla","year":"2020"},{"issue":"10","key":"10.1016\/j.jdcr.2020.05.002_bib8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.3720","article-title":"The impact of JAK-STAT signaling on muscle regeneration","volume":"20","author":"Doles","year":"2014","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"10.1016\/j.jdcr.2020.05.002_bib9","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/annrheumdis-2019-eular.7509","article-title":"FRI0131 Elucidating the mechanism underlying creatinine phosphokinase upregulation with Upacitinib","volume":"78","author":"Queeney","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512620303453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512620303453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:21:48Z","timestamp":1762474908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512620303453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2352512620303453"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2020.05.002","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2020.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}